9826 LFRCA, LLC v. Hurwitz et al, No. 3:2013cv01042 - Document 23 (S.D. Cal.
2014) case opinion from the Southern District of California U.S. Federal District ...
Jun 3, 2004 ... Hurwitz H(1), Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, ... with IFL
plus bevacizumab than with IFL plus placebo (11.0 percent vs.
Jul 23, 2013 ... Herbert I. Hurwitz, <sup>corresponding author</sup> ... variables by treatment (chemotherapy
with or without placebo vs. chemotherapy plus bevacizumab), stratified .... The
fixed-effects model was based on methodology by Parmar et al.